frequency of exercise decreased to approximately 50%. Current exercises: swimming, walking, bicycling, gardening, breath exercise. She also did qi gong-19 postures.
Musculoskeletal issues: No problems reported with posture, gait, or coordination. Supplement history: Patient has always taken supplements. Prior to diagnosis, she took a multivitamin with kelp, and cod liver oil.
Emotional/stress factors: Patient characterizes herself as a fearful person, always worrying. She has a deep faith in God and the body's ability to heal itself. She has tried to maintain a positive attitude throughout the course of her illness.
Marital/home issues: Patient characterizes her marriage as very loving and reports that she and her husband are supportive of each other. Husband is healthy. Current symptoms/date started: Dizziness on change of position (June 2001 ) , difficulty swallowing (November 2000) , chest pain (January 2001), shortness of breath when ascending 1 flight of stairs (since surgery), belching (since surgery), getting up 3 times at night to urinate, avoiding foods (hard crusts) (since surgery), trembling in extremities (hands) (since surgery), fatigue with no obvious reason (since surgery), change in hair texture (since surgery).
Life patterns: Childhood regarded as happy; middle child. More recent concern about adult children. During working career, had stress due to expectations for job performance. Wishes to let go of anxiety, concern about adult children, keep positive attitude about cancer. Activities for relaxation: exercise, reading, needlework, and travel. Interested in good diet, exercise, and relaxation techniques. Currently uses some tapes for imaging relaxation and has made an area at home to meditate (20 minutes per day). Enjoys being outdoors, adapts well to change. 
Radiation Oncology Analysis
This presentation highlights many of the tenets of multidisciplinary approaches to cancer care that have been fostered in recent years to maximize symptom management, local control, and overall survival, especially for patients with good performance status. This woman's symptom presentation for esophageal cancer is typical: dysphagia progressing over months, yet accompanied by initial negative diagnostic evaluations. Risk factors including smoking, alcohol, and possibly reflux (Pepcid AG° use) coupled with chronic life stressors are noteworthy, and with persistence, pathology becomes evident. In the United States, esophageal cancers constitute approximately 5% of all diagnoses, usually in a 3:1 male:female ratio, with an increasing predilection for distal esophageal and gastroesophageal junction locations, felt to be related to heightened incidences of chronic reflux states and the metaplastic transition from squamous to gastric mucosal surfaces, and the development of Barrett's lining, although not confirmed in this instance. Her diagnostic evaluation, appropriately comprising esophagogastroduodenoscopy and subsequent demonstration of an adenocarcinoma on pathology review, is all too common against a backdrop of a chronic inflammatory state, sometimes found in association with chronic gastric infections such as Helicobacter Pylori although testing for this is not noted.
Once the diagnosis is established, traditional clinical staging evaluation is paramount to accurate pretreatment tumor burden assessment and, thus, both staging and sequencing of interventions. The original computed tomography chest/abdomen/pelvis being negative in December 2000, and then suggestive of anatomic irregularities reflects the likelihood that the patient's local disease volume was relatively rapidly escalating, with quicker volume-doubling times for tumor; one notes the lobulated, irregular features of the gastroesophageal junction, which can be difficult to interpret relative to adequate oral contrast distension and accurate imaging, but is consistent with locally advanced, likely transmural, disease. In distal esophageal and gastroesophageal junction tumors, regional nodes include paraesophageal, pericardial, and various regional stomach nodal sites, which are presumptively positive given their evolution over a few months and size differential. Recent advances in esophageal ultrasound have enhanced the documentation of local disease permeation of the esophagus and are aptly correlated with computed tomography findings. Emerging on the scene to further enhance pretreatment cancer extent is positron emission tomography, which may indicate further micrometastatic deposits in normal-sized nodes, and regional to distant spread, especially in conjunction with image fusion techniques using computed tomography or magnetic resonance imaging. These advances can further empower managing physicians as to true disease extensions beyond the gross extensions and assist in both tailoring preoperative radiation portals and augmenting the surgeon's clinical acumen in planning the required aggressive radical resections needed to maximize local control.
Finally, in the staging evaluation data, a key concern is noted of significant weight loss from 165 to 133 pounds, likely multifactorial in nature (disease burden, tumor location with heightened symptoms of reflux and nausea secondary to vagus nerve irritation, obstructive, mechanical factors and global effects including anorexia, and side effects of chemoradiation treatment). Moreover, laboratory data including a lowered lymphocyte count, lowered albumin, and mild anemia suggest lowered immune state and likely nutritional compromise; cancer markers are not stated, but liver function tests are presumed normal. In preparation for a multidisciplinary approach and given the tumor's location in the gastroesophageal junction, appropriate attention is given to nutritional support via a Jtube, which, although a more invasive procedure than placement of a G-tube, is required to eliminate placement near potential disease extension into the stomach and to reduce potential complications.
The patient's clinical staging prior to intervention would likely be cT3 on the basis of transmural extension of disease, but because of extension into the stomach cardia, cT4, the nodal regional disease extent would make her cNl. The computed tomography report notes no distant disease (which would include celiac axis and/or upper mediastinal noncontiguous stations), so the final pretreatment clinical staging would be cTNM stage III (cT3-4 cNl cMX-0 G2) infiltrating adenocarcinoma of the distal esophagus and gastroesophageal junction. Of particular note, subsequent to neoadjuvant chemoradiation efforts, the tumor was downstaged, which occurs in approximately 50% to 60% of situations, 25% of which are often pathologic complete responses. The pathologic state would likely be pTNM stage IIB (pT2 RO pNl MX G3), and with the remaining 3 nodes positive, the risks for both locoregional failure and systemic progression are somewhat ominous, approaching 50% or better. It is important to note that often in the clinical setting, the staging and management of transdiaphragmatic tumors is a clinical challenge on virtually all fronts.
In recent years, the multidisciplinary management for locally advanced distal esophageal/ gastroesophageal junction tumors has shifted toward presurgical downstaging, which provides for potential immediate symptom management and nutritional stabilization. It also diminishes the opportunity for the patient's disease to dictate rapid progression to blatant metastatic disease that might obviate aggressive local resection except for resistant disease, which warrants a palliative resection such as bypass. Although many protocols have been proferred, the selection of cisplatinum/5-FU infusion in conjunction with conventionally fractionated external beam radiation therapy is a standard regimen with overall good tolerance and opportunity for tumor burden clearing. The treatment portals are relatively straightforward, including all measurable gross disease and its contiguous extensions into the adjacent nodal regions. Caution is warranted as to limiting morbidity profiles to the heart, liver, and, due to the tumor location, left kidney. This is now achieved through more refined treatment-planning algorithms including dose-volume histograms, complex 2-and 3-dimensional treatment planning, and multiple high-energy (usually greater than 6-MV photons) beams appropriately shaped for maximal shielding of noncritical structures. This anatomical terrain's location adjacent to symptom-producing structures (especially the gastroesophageal junction and vagus nerve/antral associations) makes the event of significant nausea, vomiting, and dehydration more likely and further supports the notion of adequate fluid and nutritional support via enteral routes (J-tube feeding) and antiemetics. The dose of 4500 cGy in 25 fractions is a typical dose for addressing microscopic disease extensions and is enhanced by the radiosensitizing effects of both cisplatinum and fluorouracil; recently, the addition of amifostine intravenously given within 15 minutes prior to the daily radiation dose may provide further radioprotection of noteworthy esophagitis/gastritis incidences and is becoming more common in the clinical settings. One final note on radiation oncology technique: intraluminal brachytherapy, the placement of either low dose rate or, more recently, high dose rate radiation sources directly into the lumen, has no practical role here, since impending obstruction, bleeding, and so on are not present, and since there would be limited penetration into the full thickness of the lesion.
It is imperative that an adequate elapse of time from the completion of preoperative programs of chemoradiation to definitive resection be allowed for maximal evolution of downstaging. Then, in the absence of obvious disease progression, primary surgical resection of all gross disease and its extensions can be achieved, with the surgeon marking any areas of obvious residual or unresectable disease and effecting appropriate anastomotic connections. The chemo-radiation treatment regimen is usually not met with any undue heightened risk for complications in the hands of experienced surgeons familiar with operations in the radiated field. Studies pioneered by Japanese researchers, in which the nodal regions have been aggressively resected to effect maximal clearing of tumor burden, have demonstrated apparent improvements in local control, and in probabilities of median and overall disease control. Assuming the patient's performance status allows, aggressive resection should be considered. Her apparent downstaging as noted in the final report is most typical and should be met by additional adjuvant chemotherapy and/or other novel integrative medicine-based interventions. Although a theoretical consideration, routine radiation oncology practices are not usually equipped to perform intraoperative radiation therapy procedures to address local extensions into adjacent tissues, or areas of gross residual disease left during resection. This intervention should, however, be strongly considered if available. Only in restricted, individualized circumstances would the use of additional postsurgical radiation therapy be employed due to dose-limiting toxicity to small intestine and other sensitive organs within the path of radiation therapy, or in the true palliative setting.
Efforts to further enhance the nutritional support for these cancer patients, including the use of antioxidants and digestive enzymes, may be appropriate given the altered pH state of the gastric mucosa and digestive surface in conjunction with adverse effects on the microbial flora of the gastrointestinal tract. More novel approaches to address nausea preoperatively and postoperatively, such as with acupuncture or acupressure techniques, can be considered, along with the use of guided imagery and visualization techniques in the immediate preoperative/postoperative setting, as well as in overall management, to reduce morbidity and enhance quality-of-life factors.
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Smoking and alcohol use are well-recognized risk factors for this histological form of esophageal cancer. In recent decades, there has been a surge of adenocarcinomas of the esophagus that are usually located in the distal esophagus and the gastroesophageal junction.
The reasons for this increase are yet uncertain, and the role of smoking and/or alcohol use is also less clear in adenocarcinoma of the esophagus. The presence of Barrett's esophagus is the most powerful risk factor for the subsequent development of esophageal adenocarcinoma and is currently regarded by some experts as a premalignant lesion. The presence of severe dysplasia in a Barrett's metaplasia is associated with a high likelihood of current presence or future development of in situ or invasive distal esophageal malignancies. Oncology practice dictates that histological confirmation of the presumed cancer diagnosis be established through the biopsy of a suspicious primary or metastatic lesion. This is critical given the implications associated with being diagnosed with cancer of the esophagus and the terribly toxic treatment modalities that are currently in use for the management of this type of malignancy. In esophageal cancer, a pathological diagnosis is usually reached through direct biopsy of the primary tumor, under direct endoscopic visualization. Less commonly, definitive pathological confirmation is reached through imaging-guided biopsy of a metastatic lesion. Once a histological diagnosis is established, the overall tumor burden is ascertained through a number of staging studies. Computed
